Blockbusters to New-Engine Drugs: The Key Industry Shift
Over the next ten years, blockbuster drugs will underperform industry-wide growth and fail to reverse the growth crisis. In their place, new-engines drugs, products for more severe conditions with a higher margin of therapeutic efficacy, will emerge as the leading force in industry growth, accounting for over 60% of industry dollar growth. They'll be more commonly discovered, less susceptible to generic competition and payor price pressures, and more compelling for prescribers. Companies should immediately begin to reassess their portfolios and refocus their discovery and development efforts. Key actions include giving new-engine drugs a more accurate weighting and letting go of the blockbuster model.
By Brian R. Buxton and Robert J. Easton
Those who view the past decade as one of continuous growth for the pharmaceutical industry often forget that early in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.